PLoS ONE (Jan 2016)

Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses.

  • Stuart D Dowall,
  • Victoria A Graham,
  • Emma Rayner,
  • Laura Hunter,
  • Robert Watson,
  • Irene Taylor,
  • Antony Rule,
  • Miles W Carroll,
  • Roger Hewson

DOI
https://doi.org/10.1371/journal.pone.0156637
Journal volume & issue
Vol. 11, no. 6
p. e0156637

Abstract

Read online

Crimean-Congo Haemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. There is no approved vaccine currently available against CCHF. The most promising candidate, which has previously been shown to confer protection in the small animal model, is a modified Vaccinia Ankara virus vector expressing the CCHF viral glycoprotein (MVA-GP). It has been shown that MVA-GP induces both humoral and cellular immunogenicity. In the present study, sera and T-lymphocytes were passively and adoptively transferred into recipient mice prior to challenge with CCHF virus. Results demonstrated that mediators from both arms of the immune system were required to demonstrate protective effects against lethal challenge.